Compelling evidence support the view that PrPC may mediate protection of CSC from apoptosis, along with the acquisition of multidrug resistance (MDR), which in turn are responsible of treatment failure, tumor recurrence, and poor survival of cancer patients [30,48]. This evidence concerns the gene PRNP and neoplasm.